Removal of TSE agent from plasma products manufactured in the United Kingdom

Vox Sanguinis

Volumn 104, Issue 4, 2013, Pages 299-308

  Roberts, P L ^a   Dalton, J ^a   Evans, D ^a   Harrison, P ^a   Li, Z ^a   Ternouth, K ^a   Thirunavukkarasu, V ^a   Bulmer, M ^a   Fernando, S ^a   McLeod, N ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Biosafety; Manufacturing steps; Plasma products; TSE agent removal; VCJD

Indexed keywords

ALBUMIN; ALCOHOL; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BRAIN EXTRACT; COPPER; IMMUNOGLOBULIN; PRION PROTEIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD COMPONENT; FILTRATION; FRACTIONATION; ION EXCHANGE; PRION DISEASE; PRIORITY JOURNAL; PURIFICATION; SCRAPIE AGENT; UNITED KINGDOM; WESTERN BLOTTING;

BLOOD SAFETY; CREUTZFELDT-JAKOB SYNDROME; FACTOR VIII; GREAT BRITAIN; HUMANS; IMMUNOGLOBULINS; PLASMA; PRIONS; PRPSC PROTEINS;

EID: 84876714449     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12004     Document Type: Article

References (51)

1. Prusiner SB: Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie of sheep and BSE of cattle. Develop Biol Stand 1991; 75:55-74.
2. Chesebro B: Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 2003; 66:1-20.
3. Brown P, Will RG, Bradley R, et al.: Bovine spongiform encephalopathy and variant Creutzfelt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis 2001; 7:6-16.
4. Turner ML, Ironside JW: New-variant Creutzfeldt-Jakob disease: the risk of transmission of blood transfusion. Blood Rev 1998; 12:255-268.
5. Ward HJT, MacKenzie JM, Llewelyn CA, et al.: Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. Vox Sang 2009; 97:201-210.
6. Hewitt PE, Llewelyn CA, Mackenzie J, et al.: Creutzfeldt-Jacob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review Study. Vox Sang 2006; 91:221-230.
7. Peden A, McCardie L, Head MW, et al.: Variant CJD infection in the spleen of a neurological asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16:296-304.
8. Bennett P, Ball J: vCJD risk assessment calculations for a patient with multiple routes of exposure. London, UK, Department of Health, 2009.
9. Foster PR: The Removal of TSE agents from blood products. Vox Sang 2004; 2:7-10.
10. Burnouf T, Padilla A: Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13:320-328.
11. Millson GC, Hunter GD, Kimberlin RH: An experimental examination of the scrapie agent in cell membrane mixtures: II. The association of scrapie activity with membrane fractions. J Comp Pathol 1971; 81:255-265.
12. Yunoki M, Tanaka H, Urayana T, et al.: Prion removal by nanofiltration under different experimental conditions. Biologicals 2008; 36:27-36.
13. Matejtschuk P, Dash CH, Gascoigne EW: Production of human albumin solution: a continually developing colloid. Br J Anaesth 2000; 85:887-895.
14. Chidwick K, Matejtschuk P, Gascoigne E, et al.: Clinical experience with a new solvent detergent-intravenous immunoglobulin free of hypotensive effects. Vox Sang 1999; 77:204-209.
15. ®, in primary immunodeficiency disease. Clin Exp Immunol 2010; 162:510-515.
16. Winkelman L, Owen NE, Evans DR, et al.: Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang 1989; 57:97-103.
17. ®, a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A. Haemophilia 2011; 17:185-190.
18. Feldman PA, Bradbury PI, Williams JD, et al.: Large-scale preparation and biochemical characterization of a new high purity factor IX concentrate by metal chelate affinity chromatography. Blood Coagul Fibrinolysis 1994; 5:939-948.
19. Kistler P, Nitschmann H: Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7:414-424.
20. Lee DC, Stenland CJ, Hartwell RC, et al.: Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84:77-89.
21. Roberts PL, Evans D, Harris L: Removal of TSE agents by depth or membrane filtration from plasma products. Biologicals 2010; 38:158-161.
22. Kascsak RJ, Rubenstein R, Merz PA, et al.: Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 1987; 61:3688-3693.
23. de Marco MF, Linehan J, Gill ON, et al.: Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J Pathol 2010; 222:380-387.
24. Hilton DA, Ghani AC, Conyers L, et al.: Prevalance of lymphoreticular prion protein in UK tissue samples. J Pathol 2004; 203:733-739.
25. Frosh A, Smith LC, Jackson CJ, et al.: Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet 2004; 364:1260-1262.
26. Clewley JP, Kelly CM, Andrews N, et al.: Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey. BMJ 2009; 338:b1442.
27. Taylor DM: Resistance of transmissible spongiform encephalopathy agents to decontamination. Contrib Microbiol 2004; 11:136-145.
28. Fernie K, Steele PJ, Taylor DM, et al.: Comparative studies on the thermostability of five strains of transmissible-spongiform-encephalopathy agent. Biotechnol Appl Biochem 2007; 47:175-183.
29. Giles K, Glidden DV, Beckwith R, et al.: Resistance of Bovine Spongiform Encephalopathy (BSE) prions to inactivation. PLoS Pathog 2008; 4:1-9.
30. Foster PR: Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med 1999; 9:3-14.
31. Brown P: Creutzfeldt-Jakob disease: reflections on the risk from blood product therapy. Haemophilia 2007; 5:32-39.
32. Vey M, Baron H, Weimer T, et al.: Purity of spiking agents affects partitioning of prions in plasma purification. Biologicals 2002; 30:187-196.
33. Flan B, Arrabal S: Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfu Clini Biol 2007; 14:51-62.
34. Thyer J, Unal A, Thomas P, et al.: Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulin. Vox Sang 2006; 91:292-300.
35. ®, a human factor VIII/VWF complex concentrate. Haemophilia 2009; 15:1249-1257.
36. Gregori L, Maring JA, MacAuley C, et al.: Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals, 2004; 32:1-10.
37. Committee for Medicinal Products For Human Use (CHMP). European Medicines Agency: guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. CPMP/BWP/CPMP/5136/03 2004.
38. Lee DC, Stenland CJ, Millwer JL, et al.: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41:449-455.
39. Foster PR, Welch AG, McLean C, et al.: Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78:86-95.
40. Van Holden RW, Autenrieth SM: Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003; 85:20-24.
41. ® virus removal filters. Biologicals 2001; 29:17-25.
42. Van Holton RW, Autenrieth S, Bosse JA, et al.: Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion 2002; 42:999-1004.
43. ®). Biologicals 2006; 34:227-231.
44. ® manufacturing process. Haemophilia 2007; 13:580-587.
45. Davies P, Brown DR: The chemistry of copper binding to PrP: is there sufficient evidence to elucidate a role for copper in protein function?Biochem J 2008; 410:237-244.
46. Yunoki M, Tanaka H, Urayama T, et al.: Infectious prion protein in the filtrate even after 15nm filtration. Biologicals 2010; 38:311-313.
47. Burdick MD, Pifat DY, Petteway SR, et al.: Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006; 20:57-62.
48. Foster PR: Prions and blood products. Ann Med 2000; 32:501-513.
49. Det Norske Veritas: Risk assessment of exposure to vCJD infectivity in blood and blood products: report for the Department of Health, London, UK. Feb 2003.
50. Zaman SM, Hill FG, Palmer B, et al.: The risk of variant Creutzfeldt-Jakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia 2011; 17:931-937.
51. Center for Biologics Evaluation and Research, US Food and Drug Administration: A 2010 update of the draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma-derived factor VIII manufactured under United States (US) license from plasma collected in the US. Silver Spring, MD, USA, Oct 2010.